DRUGS FOR TREATMENT OF PNEUMOCYSTIS CARINII

在过去的两年里，肺孢子虫肺炎已成为主要的 获得性免疫缺陷综合征患者的机会性疾病 （艾滋病）。 该病进展迅速，死亡率超过40% 尽管治疗，而死亡率接近100%， 例 喷他脒是一种有效的化学治疗剂，但高度依赖于药物本身。 有毒 乙胺嘧啶和磺胺嘧啶的各种组合和类似物 都取得了不同程度的成功。 然而，艾滋病患者 肺囊虫肺炎患者对这种治疗反应不佳。 该合同的目的是确定新的药物， 用于治疗艾滋病肺孢子虫肺炎的潜力 患者，利用动物模型和/或体外技术。 评价 在艾滋病患者中使用这种有前途的药物， 单独的项目。

In the past two years pneumocystis pneumonia has become the major opportunistic disease in patients with acquired immunodeficiency syndrome (AIDS). The disease is rapidly progressive with a mortality rate over 40% despite treatment, whereas the mortality rate approaches 100% in untreated cases. Pentamidine is an effective chemotherapeutic agent but is highly toxic. Various combinations and analogs of pyrimethamine and sulfadiazine have been used with varying degrees of success. However, AIDS patients with pneumocystis pneumonia have not responded well to such treatment. The objective of this contract is to identify new drugs which have potential for use in the treatment of pneumocystis pneumonia in AIDS patients, utilizing animal models and/or in vitro techniques. Evaluation of such promising drugs in AIDS patients will then be carried out under a separate project.